Win a Travel Voucher worth up to SGD 2,000 and Enjoy Limited Flash Sales at Traveloka Year-End Sale!
SINGAPORE, Dec. 17, 2024 /PRNewswire/ -- Planning your year-end travel just got easier! Traveloka, Southeast Asia's leading travel platform, invites last-minute planners to turn their year-end celebrations into unforgettable holidays. From December 16, 2024, to January 3, 2025, the Traveloka Year-End Sale brings exciting flash sales on flights, hotels, attractions, and activities. As an added highlight, participants can also win a travel voucher worth up to SGD 2,000.
Last-Minute Travel Hacks for Your Year-End Getaway
Don't let last-minute planning hold you back. Try these smart tips to create the perfect year-end escape:
Book and Win Travel Voucher Worth Up to SGD 2,000!
Want to make your holiday even more exciting? Traveloka Year End Sale gives you the chance to win a travel voucher worth up to SGD 2,000! Simply book during the promotion period and stand a chance to be one of the lucky winners by joining Traveloka's social media giveaway. Full details and terms & conditions are available on Traveloka's official platforms.
Turn your year-end travel plans into reality. Download the Traveloka app now and take advantage of these fantastic deals. For updates on the Traveloka Year End Sale, visit our official website or follow us on Instagram, Facebook, and Tiktok. Traveloka First, then Travel the World!
About Traveloka
Traveloka is Southeast Asia's leading travel platform, empowering consumers to explore, book, and enjoy a wide range of travel products. The platform offers extensive transportation options, including flights, buses, trains, car rentals, and airport transfers. Traveloka's accommodation offerings are equally broad, encompassing hotels, apartments, guest houses, homestays, resorts, and villas. Additionally, the platform enhances the travel experience by offering cruise packages and access to various local attractions, such as theme parks, museums, day tours, and more.
Founded in Indonesia in 2012, Traveloka has expanded its operations to Thailand, Vietnam, Singapore, Malaysia, the Philippines, and Australia. The company is committed to providing exceptional customer service with 24/7 support available in local languages and acceptance of over 40 payment methods. With nearly 140 million app downloads and nearly 50 million monthly active users, Traveloka stands as one of the most popular travel apps in the region. For more information, please visit Traveloka.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Traveloka Reveals 3 Last-Minute Travel Hacks for Year End Getaways
REHOVOT, Israel, Dec. 17, 2024 /PRNewswire/ -- Amai Proteins, a scale-up designer of novel proteins that answer the needs of consumers and industry, has succesfullly completed world's first double-blind, random clinical trial on the effects of their proprietary hyper-sweet protein, sweelin®, on blood glucose and insulin levels in humans.
The study demonstrated that sweelin® neither raises blood glucose nor blood insulin levels in healthy adults even after consuming an amount equivalent to the sweetness of 75 grams of sugar (in the form of glucose).
Although not required by regulatory authorities, Amai Proteins decided to conduct this study to boost consumer and market confidence in the safety and health profile of sweelin®. The study provides validated evidence of the beneficial effects of sweelin® on consumer's health. sweelin® can help consumers globally who are trying to reduce added sugars in their diet but don't want to compromise on taste or health.
The study was conducted at the Phase 1 Clinical Research Center (CRC) of Tel Aviv Sourasky Medical Center, under strict Good Clinical Practice (GCP) standards. Twenty eligible healthy volunteers completed the screening process and participated in the study.
All participants made three visits to the medical center. During each visit, the participants consumed one of three test beverages sweetened by either sweelin®, glucose, or stevia in a crossover double-blind, randomized controlled manner. All beverages were matched for sweetness intensity, with their dosage aligned to the sweetness equivalent of 75 grams of glucose, as used in a standard Oral Glucose Tolerance Test (OGTT). The study monitored the participants' response to the test beverages for 120 minutes after consumption, measuring postprandial blood glucose and insulin levels.
All the participants successfully completed the study with no test-item-related adverse events, and no dropouts.
For the first time, this study by Amai proteins confirmed that a high dose of sweelin®, which can be labelled as 'serendipity berry sweet protein', does not impact blood glucose or insulin levels in healthy individuals.
About Amai Proteins
Amai Proteins develops novel proteins which answer the needs of consumers and industry. Our first product, sweelin®, is a calorie-free sweet protein designed to significantly replace sugar and sugar alternatives in a wide variety of food & beverages including soft drinks, fruit juice, dairy products, sauces, spreads, dressings, snacks, peanut butter, and much more. Our solutions are inspired by nature and built with biology through a natural fermentation process. With our Pro3 platform, Amai Proteins aims to create future breakthroughs in the world of meat, plant and milk proteins.
www.amaiproteins.com or visit our official LinkedIn and YouTube channels.
For more on sweelin®, visit sweelin.com
For more information:
Dr. Ilan Samish, Founder & CEO, Amai Proteins
press@amaiproteins.com
Video - https://www.youtube.com/watch?v=nFx1yM-8qL0
Video - https://youtu.be/8p58pIhJi-I
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Amai Proteins succesfully completed world's first human clinical trial on effects of sweet proteins, with sweelin®
